FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide ...

The project, led by a team from the University of the West of England (UWE), aims to increase the visual representation of ...

The plant, also known as sticky weed, goosegrass or Galium aparine, has been used for centuries as a natural remedy for ...

He’s on his way to becoming Ireland’s next big pop star, but Bradley Marshall is taking it all in his stride. The 24-year-old ...

In type 1 diabetes, the body’s own immune system turns against the pancreas. Cells meant to protect you start destroying ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Good day, and welcome to Arcutis Biotherapeutics 2025 first-quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now ...

A fundraiser is coming up to help inform the public about a disease that affects millions of people across the country and ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

SINGAPORE - An air of disappointment hung over Serangoon Stadium, where WP supporters and members had gathered late on May 3 to await the results of the general election. Many had turned up with ...

Psoriasis and rheumatoid arthritis are both autoimmune diseases. While they affect your body in different ways, they share some common elements. And some research suggests that having one of these ...